LCT Presentation at American Diabetes Association

LCT Presentation at American Diabetes Association

• Confirms DIABECELL® initial Phase I/IIa trial objectives met

• Concludes DIABECELL® as potential treatment for unstable Type1 diabetes

28 June 2010: Sydney, Australia & Auckland, New Zealand. Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), a global company pioneering the development of cell implants to treat diabetes, today announced that its DIABECELL® Phase I/IIa clinical data was presented at the 70th Scientific Session of the American Diabetes Association (ADA) on June 27 in Orlando, Florida by Professor Boris Draznin, Director, Adult Diabetes Program, University of Colorado Denver, School of Medicine. The ADA annual conference is the world’s largest and most prestigious diabetes meeting, attended by over 20,000 members of the professional diabetes community including physicians, scientists, and other clinicians and health care professionals.

LCT’s lead product, DIABECELL®, comprises encapsulated neonatal pancreatic islets that are implanted into the abdomen of patients using a simple laparoscopic procedure. Professor Draznin’s presentation on the use of DIABECELL® to treat Type 1 diabetes concluded that it is possible to achieve therapeutic success without immunosuppression. The results of the first trial established proof of concept in humans and safety objectives have been met. DIABECELL® is presently in a dose escalating Phase II clinical trial in New Zealand.

“There is growing acknowledgment by the diabetes medical community globally that DIABECELL® holds great promise in providing an improved treatment for Type 1 diabetes,” said Professor Bob Elliott, LCT Medical Director.

ENDS

© Scoop Media